# RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

> **NCT00576680** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 43 (actual)

## Conditions studied

- Pancreatic Neuroendocrine Tumor

## Interventions

- **DRUG:** RAD001
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00576680
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2019-03-29
- **Final completion:** 2019-03-29
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2020-07-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00576680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00576680, "RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00576680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*